A Computationally Designed Water-Soluble Variant of a G-Protein-Coupled Receptor: The Human Mu Opioid Receptor

Jose Manuel Perez Aguilar
University of Pennsylvania, perezagu@sas.upenn.edu

Jin Xi
Felipe Matsunaga
Xu Cui
Bernard Selling

See next page for additional authors

Follow this and additional works at: https://repository.upenn.edu/chemistry_papers

Part of the Biochemistry Commons, Organic Chemistry Commons, and the Physical Chemistry Commons

Recommended Citation
Perez Aguilar, J., Xi, J., Matsunaga, F., Cui, X., Selling, B., Saven, J. G., & Liu, R. (2013). A Computationally Designed Water-Soluble Variant of a G-Protein-Coupled Receptor: The Human Mu Opioid Receptor. PLoS ONE, 8 (6), e66009-1-e66009-10. http://dx.doi.org/10.1371/journal.pone.0066009

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/chemistry_papers/24
For more information, please contact repository@pobox.upenn.edu.
A Computationally Designed Water-Soluble Variant of a G-Protein-Coupled Receptor: The Human Mu Opioid Receptor

Abstract

G-protein-coupled receptors (GPCRs) play essential roles in various physiological processes, and are widely targeted by pharmaceutical drugs. Despite their importance, studying GPCRs has been problematic due to difficulties in isolating large quantities of these membrane proteins in forms that retain their ligand binding capabilities. Creating water-soluble variants of GPCRs by mutating the exterior, transmembrane residues provides a potential method to overcome these difficulties. Here we present the first study involving the computational design, expression and characterization of water-soluble variant of a human GPCR, the human mu opioid receptor (MUR), which is involved in pain and addiction. An atomistic structure of the transmembrane domain was built using comparative (homology) modeling and known GPCR structures. This structure was highly similar to the subsequently determined structure of the murine receptor and was used to computationally design 53 mutations of exterior residues in the transmembrane region, yielding a variant intended to be soluble in aqueous media. The designed variant expressed in high yield in Escherichia coli and was water soluble. The variant shared structural and functionally related features with the native human MUR, including helical secondary structure and comparable affinity for the antagonist naltrexone (Kd = 65 nM). The roles of cholesterol and disulfide bonds on the stability of the receptor variant were also investigated. This study exemplifies the potential of the computational approach to produce water-soluble variants of GPCRs amenable for structural and functionally related characterization in aqueous solution.

Disciplines

Biochemistry | Organic Chemistry | Physical Chemistry

Author(s)

Jose Manuel Perez Aguilar, Jin Xi, Felipe Matsunaga, Xu Cui, Bernard Selling, Jeffery G. Saven, and Renyu Liu

This journal article is available at ScholarlyCommons: https://repository.upenn.edu/chemistry_papers/24
A Computationally Designed Water-Soluble Variant of a G-Protein-Coupled Receptor: The Human Mu Opioid Receptor

Jose Manuel Perez-Aguilar1,*, Jin Xi2,*, Felipe Matsunaga2, Xu Cui2,3, Bernard Selling4, Jeffery G. Saven1*, Renyu Liu2 *

1 Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 2 Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 3 Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing, China, 4 Impact Biologicals Inc., Swarthmore, Pennsylvania, United States of America

Abstract

G-protein-coupled receptors (GPCRs) play essential roles in various physiological processes, and are widely targeted by pharmaceutical drugs. Despite their importance, studying GPCRs has been problematic due to difficulties in isolating large quantities of these membrane proteins in forms that retain their ligand binding capabilities. Creating water-soluble variants of GPCRs by mutating the exterior, transmembrane residues provides a potential method to overcome these difficulties. Here we present the first study involving the computational design, expression and characterization of water-soluble variant of a human GPCR, the human mu opioid receptor (MUR), which is involved in pain and addiction. An atomistic structure of the transmembrane domain was built using comparative (homology) modeling and known GPCR structures. This structure was highly similar to the subsequently determined structure of the murine receptor and was used to computationally design 53 mutations of exterior residues in the transmembrane region, yielding a variant intended to be soluble in aqueous media. The designed variant expressed in high yield in Escherichia coli and was water soluble. The variant shared structural and functionally related features with the native human MUR, including helical secondary structure and comparable affinity for the antagonist naltrexone (Kd = 65 nM). The roles of cholesterol and disulfide bonds on the stability of the receptor variant were also investigated. This study exemplifies the potential of the computational approach to produce water-soluble variants of GPCRs amenable for structural and functionally related characterization in aqueous solution.

Citation: Perez-Aguilar JM, Xi J, Matsunaga F, Cui X, Selling B, et al. (2013) A Computationally Designed Water-Soluble Variant of a G-Protein-Coupled Receptor: The Human Mu Opioid Receptor. PLoS ONE 8(6): e66009. doi:10.1371/journal.pone.0066009

Editor: Yang Zhang, University of Michigan, United States of America

Received February 21, 2013; Accepted April 30, 2013; Published June 14, 2013

Copyright: © 2013 Perez-Aguilar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Foundation for Anesthesia Education and Research (FAER) (PI, RL), National Institutes of Health (NIH) K08 (K08-GM-093115-01) (PI, RL), GROFF (PI, RL), the Department of Anesthesiology and Critical Care at the University of Pennsylvania (PI, RL), and the Penn Nano/Bio Interface Center through the National Science Foundation (NSF) NSEC DMR-0425780 (PI, JGS). NSF MIREC DMR-1120901 (JGS) provided infrastructural support related to protein computational work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors of this manuscript declare that there is no competing interest among authors. Dr. Bernard Selling is the president of Impact Biologicals. Impact Biologicals is not involved in any projects that will financially benefit (or be harmed) by publication of this work. Including Dr. Bernard Selling as one of the coauthors does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: liur@uphs.upenn.edu (RL); saven@sas.upenn.edu (JGS)

Current address: Department of Physiology and Biophysics, Weill Cornell Medical College, New York, New York, United States of America

These authors contributed equally to this work.

Introduction

The G-protein-coupled receptor (GPCR) family of proteins have important roles in signal transduction and cellular response to extracellular stimuli [1] and are the targets of many pharmaceuticals. Drug development and the study of the molecular mechanisms of (GPCRs) are impeded by limited solubility and difficulty in isolating sufficient quantities of functional receptors. These difficulties are caused in part by the large numbers of hydrophobic residues on the transmembrane, lipid-contacting protein exterior. To circumvent these problems, water-soluble variants of GPCRs can potentially be identified by systematically redesigning these exterior residues. Along these lines, computational protein design has been used to create water-soluble analogs of transmembrane proteins that can be expressed in E. coli and that retain structural and functional features of their parent membrane proteins [2,3], e.g., the bacterial potassium channel (KcsA) [4] and a transmembrane domain of the nicotinic acetylcholine receptor (nAChR) [5]. Herein, such design is extended to a member of the GPCR superfamily, where comparative modeling is used to identify exterior residues in the transmembrane region.

The mu opioid receptor (MUR) is a GPCR that is the dominant target of opioids, many of which are potent analogs of morphine [6]. Opioid use has soared in recent years [7–9], and human MUR has been linked to many of its notorious side effects, including addiction and deadly respiratory depression [6,7]. The molecular mechanisms governing GPCR function remain obscure despite the profound insights obtained recently from multiple high-resolution crystal structures [10–18].
Here computational redesign to increase water solubility while retaining functionally related properties was applied to the human MUR. In previous redesign efforts, template structures were derived from experimental structures of KcsA (via X-ray diffraction) [4,19] and nAChR (via cryo-electron microscopy) [5,20]. Often with membrane proteins (including GPCRs), such experimentally determined structures are not available. No structure for the human MUR was available when this study was initiated, thus the approach was extended to include structural modeling. The design involved several key steps: (i) Comparative modeling using sequence alignment and known GPCR structures (the subsequently solved structure of murine MUR provided a means to assess the quality of the comparative model [15]); (ii) Identification and co mutational redesign of transmembrane exterior residues; (iii) Overexpression in E. coli and purification; (iv) Characterization of structural and ligand-binding properties in aqueous buffer. The designed water-soluble human MUR has structurally and functionally related properties comparable to the native membrane-soluble human MUR.

Materials and Methods

Computational Protein Design

Bovine rhodopsin (UniProtKB accession number P35372; PDB accession code: 1U19 [11] and the b2 adrenergic receptor (UniProtKB: P02699; PDB: 2RH1) [12] were used as templates in the creation of models of the human MUR transmembrane domain (UniProtKB: P07550) [21]. Pairwise sequence alignments of the human mu opioid receptor with bovine rhodopsin and with the b2 adrenergic receptor were carried out using BLASTp [22] with the Blosum62 substitution matrix [23]. In a multiple sequence alignment, adjustments were performed to maintain highly conserved residues of the class A GPCR family [24]. One hundred independent models of a protein structure comprising residues S66 to C353 were generated using Modeller 8v2 [25]. The structure was validated using molprobity [26] and then validated a posteriori by the recently solved crystal structure of the murine mu opioid receptor [15].

Protein Expression and Purification

The synthetic cDNA encoding of the transmembrane-only water-soluble MUR variant (wsMUR-TM) was produced by DNA2.0 Inc. (Menlo Park, CA). The sequences were subcloned between the NdeI and XhoI restriction sites of the expression plasmid pET-28b (+) (EMD/Novagen). E. coli BL21(DE3) cells (EMD/Novagen) were used for expression. Cells were grown in shake flasks with Lysogeny broth medium with 30 μg/mL kanamycin to an OD of 1.0, induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 h at 37 °C, then pelleted by centrifugation. Cell pellets were stored at 20°C until purification. For solubility testing, 1 OD aliquots of cells were pelleted in microcentrifuge tubes, suspended in 150 μL of TE (50 mM Tris-HCl, 1 mM EDTA, pH = 8.0), then shaken with 0.5 g of glass beads (0.1 mm diameter) for 5 min. Aliquots of the resulting lysates were spun in a microcentrifuge for 1 min. Aliquots of total lysate, or the supernatant and pellet fractions after centrifugation, were analyzed on reducing sodium dodecyl sulfate (SDS) gels.

Frozen cells from 250 mL of fermentation (500–550 ODs) were thawed, and then suspended in 33.5 mL of 50 mM Tris-HCl, 1 M urea, pH = 8.0. Once the pellet was fully resuspended, EDTA was added to 1 mM, Triton X-100 to 1%, and hen egg lysozyme to 1 μg per OD of cells, in a total volume of 37 mL. After the slurry was incubated for 20 min at room temperature (RT), MglCl was added to 3 mM, followed by 100 units of benzonase. The suspension was swirled, incubated another 5 min at RT, and then spun in an Oak Ridge tube at 10,000 rpm for 20 min at 20°C in an SS-34 rotor (ravg = 6.98 cm, rmax = 10.70 cm).

The resulting pellet was resuspended into 35 mL of 50 mM Tris-HCl, 1 M urea, pH = 8.0. Triton X-100 (1.5 mL of a 25% solution) and 2-mercaptoethanol (2-ME) was added to 40 mM. The tube was inverted several times, and then spun as above.

The following steps were designed to resemble those that had been used to dissolve and purify recombinant forms of native mu opioid receptor. The pellet from the above washes was resuspended into 5 mL of buffer phosphate Tris buffer (100 mM phosphate, 10 mM Tris, adjusted to pH = 8.0 with NaOH) and dispersed by drawing through a pipet followed by a 25 gauge needle. The volume was then raised to 37 mL by addition of phosphate Tris buffer, and 2-ME was then added to 40 mM. The tube was inverted to mix, then spun as above.

The resulting pellet was dispersed into 36 mL of PT as described above. The suspension was then mixed with an equal volume of phosphate Tris buffer containing 0.2% SDS and 10 mM 2-ME. The suspension was rocked until it became almost clear (60–90 min). The suspension was then poured into two 38 mL Oak Ridge tubes. These were spun tube at 12,000 rpm for 20 mins at 20°C in an SS-34 rotor.
Mass Spectrometry

The appropriate protein band from an SDS-PAGE gel was excised and digested with trypsin. Peptides were injected into a nano-LC/MS (10 cm C18 capillary column) to be separated by Eksigent. NanoLC proteomics experiments were run at 200 nL/min for 60 min with gradient elution. Nanospray was used to spray the separated peptides into LTQ (Thermo Fisher Scientific, MA). The raw data was acquired by Xcalibur (Xcalibur, Inc. Arlington). Sequest (http://fields.scripps.edu/sequest/) was used to search the database Uniprot_Sprot, Scaffold 2.6 (Proteome Software, Inc. OR) was used to combine and analyze the Sequest generated data quantitatively by using spectrum count.

Circular Dichroism and Thermal Stability

Circular dichroism (CD) spectra were recorded by using CD Spectrometer (Chirascan, AppliedPhotophysics Limited, Leatherhead, United Kingdom) with a scan speed of 1 nm/s and 1 mm path length. Corresponding blanks were used for calibration for each assay and subtracted from raw data. Two data sets were recorded and averaged to increase the signal-to-noise ratio. The CDNN CD spectra deconvolution software [33] was utilized to determine the second order conformation content of the proteins. CD spectroscopy for wsMUR-TM at different temperatures were recorded with 6 μM of the receptor in buffer (5 mM sodium phosphate, pH = 7.0) from 10°C to 90°C in increments of 2°C per min. Absorbance was maintained lower than 1.0 to ensure sufficient light transmission. The temperature-dependence curve was plotted using GraphPad Prism (version 5, GraphPad Software, Inc. La Jolla).

Protein Unfolding and Thermal Stability

The CD spectra of the protein was determined in the presence and absence of 8 M urea with and without 2-ME (25 mM or 200 mM, 5 mM sodium phosphate, 0.01% SDS, pH = 7.0). The final samples contained protein diluted to 6 μM and the requisite dilutions of urea and 2-ME. Each sample was incubated at room temperature for 1 h.

CD spectroscopy was utilized to investigate the thermostabilization of wsMUR-TM by cholesterol. The CD spectra were recorded with a 6 μM of the receptor (0.27 mg/ml) in buffer (5 mM sodium phosphate, 0.01% SDS, pH = 7.0) from 10°C to 90°C. 0.01% SDS was used since cholesterol can be dissolved in SDS solution. Cholesterol with 1:1 molar ratio to the protein was used. The thermostability determination protocol is similar as described above.

Protein unfolding was also studied by monitoring the intrinsic tryptophan fluorescence of the protein. A RF-5301PC spectro-fluorophotometer (Shimadzu North America, Columbia, MD) was used to monitor fluorescence emission following excitation at 295 nm. Samples were prepared as in CD unfolding experiments. Samples were measured in duplicate and results reflect averaged values of each trial.

Homogeneous Time-Resolved Fluorescence (HTRF)

Based Binding Assay

The fluorescent binding assay employs the native MUR fused at the N-terminus to a SNAP-tag® enzyme and expressed on HEK293 cells. SNAP-tag-mu-opioid is then covalently labeled with terbium cryptate (Lumi4-Tb), a long lifetime FRET donor. An analog of the potent opioid antagonist naltrexone that contains the d2 dye (red-naltrexone) is used as the fluorescence energy transfer acceptor. Upon ligand binding, a FRET process occurs between the Lumi4-Tb donor (emission at 620 nm) and SNAP-Lumi4-Tb-mu-opioid receptor and the red-naltrexone acceptor (emission at 665 nm). The fluorescence emission from the acceptor is detected in a time resolved manner (TR-FRET). For HTRF assay (Cisbio Bioassays, Bedford, MA), Tag-lite® mu opioid cells suspended in culture medium were dispensed in white 384-well low-volume microplates (Greiner Bio-one Greiner Bio-One North America, Monroe, NC) at 3700 cells/10 μL/well. Tag-lite mu opioid labeled cells with 60 nM of Tag-lite m opioid labeled cells with 60 nM of Tag-lite opioid receptors red-naltrexone, and 5 μL of the wsMUR-TM with 11 further 1:2 serial dilutions from the μM to the mM range. All samples were mixed with final volume 20 μl and incubated at RT for 2 h. After incubation, HTRF signals were measured using a plate reader (BMG, Cary, NC) after excitation at 337 nm at both 620 and 665 nm emission. HTRF signal was calculated as a two-wavelength signal ratio: (peak intensity 665 nm/peak intensity 620 nm)]. IC50 determination and statistical analysis IC50 values for wsMUR-TM were determined by fitting the dose-responses curves using the Prism program (GraphPad Software, San Diego, CA).

Results

Computational Design of a Water-Soluble Variant of the Human MUR

A comparative model of the human MUR transmembrane domain (288 residues, comprising sites 66–353) was obtained using known GPCR structures [25] (Figure 1). Based upon surface accessibility, 55 exterior transmembrane residues were selected for the computational redesign. As described in previous work, the calculations identify the probabilities of amino acids at variable positions among sequences that are expected to be water soluble by imposing overall energetic constraints such that (a) the amino acids are consistent with the remainder of the protein in terms of steric, electrostatics and hydrogen-bonding (as guided by a molecular force field) and (b) a solvent or environmental energy is constrained to have a value expected for a globular protein of the same length, yielding extrahydrphilic residues expected for a water-soluble protein [4,5]. A first calculation identified 31 of the targeted positions as having a strong preference for one amino acid, i.e., those sites where the probability one amino acid exceeded 0.8: A75E, S78K, I40, L79K, A199E, V83E, F45, F89, I93E, T120E, 6.55, K187K, E4.43, I188E, 4.44, V93E, 3.53, C192K, 4.48, I199E, A205E, 6.61, N232D, 3.26, N232D, L233K, 3.37, I240K, 5.44, F241K, 3.45, I244H, 5.39, M245E, 5.49, L248K, 5.32, V252E, 5.56, A289E, 6.42, V293K, 5.46, P297T, 6.30, I300K, 5.33, I303K, 5.36, I304E, 6.57, A306K, 6.59, A308K, 7.41, and V336K, 7.51. The superscript notation is consistent with the Ballesteros and Weinstein indexing system: (number of the transmembrane helix).(residue number relative to most conserved residue in transmembrane helix), which is assigned position 50 [34]. These mutations were introduced, and the corresponding residue identities were fixed in subsequent calculations. Similarly, second and third calculations respectively specified one (V82F, 1.44, and two (T72K, 1.34, and L333E, 1.48) additional mutations. From the results of a fourth calculation, the most probable amino acid was selected at the remaining 21 positions, yielding a sequence and model structure for wsMUR-TM as presented in Figure 1. The designed sequence is presented in figure 2A.

The recent structure of the closely related murine MUR provides an opportunity to evaluate the structure and the location of the mutated positions in wsMUR-TM [13]. The human and murine receptors have 94% sequence identity. The model of the human MUR and the murine crystal structure superimpose well (Figure 2B), particularly with regard to the transmembrane helices
Only five positions in wsMUR-TM were not located in the exterior of the murine structure (T120E, Y130K, N232D, K305G, and A306K) and could in principle affect ligand binding (Figure 2C). In the murine structure, however, these five positions residues were not among the residues that directly contact beta-Funaltrexamine (β-FNA), an irreversible antagonist of the receptor (15).

Overexpression, Purification, and Verification of wsMUR-TM

Attempts to express the native full-length human MUR in *E. coli* were unsuccessful presumably due to the protein’s toxicity. In contrast, wsMUR-TM expressed well and was isolated with high purity using affinity chromatography (Figure 3A). The yield was 20 mg/L of shake flask culture. An initial exposure to 0.1% sodium dodecyl sulfate (SDS) was required to purify the receptors. After dialysis to remove non-bound SDS, the purified variant was soluble at 6 mg/mL in buffer solution (130 mM NaCl, 20 mM NaHPO₄, pH = 7.0). Using mass spectrometry (MS), fragments of the wsMUR were identified covering 37.6% of the designed sequences. One of the identified fragments of the receptor is presented in Figure 3B.

Secondary Structure of wsMUR-TM

The secondary structure of the water-soluble variant was determined through circular dichroism (CD). The CD spectra indicated predominantly helical structures with a helical secondary structure content of ~48% (estimations based on the molar ellipticity over the range 205 to 260 nm). The comparison of the helical content with that of the native human MUR expressed in yeast system in the presence of high concentration of detergent (0.1% SDS) is presented in table 1.

Thermal Stability, Cholesterol Interaction, and Conserved Disulfide Bond

As monitored by CD, wsMUR-TM started to lose ellipticity significantly near 62°C and was almost fully unfolded at 90°C (Figure 4). The stability of wsMUR-TM was also investigated.
Figure 2. (A) Sequences of the crystal structure of the mouse mu opioid receptor (PDB code 4DKL; top) (1) and the human water-soluble variant wsMUR-TM (bottom). The murine sequence (top) corresponds to that whose structure is presented in the crystal structure of the mouse mu opioid receptor. The helical secondary structure assigned with Stride [56] is shown as yellow rectangles. The gray residues in between TM5 and TM6 (MLSGSK) are absent in the crystal structure. The helical secondary structure of the wsMUR-TM model assigned with Stride is shown as blue lines. (B) Superposition of the mouse mu opioid receptor (yellow) and the wsMUR-TM model (blue). (C) Rendering from the “extracellular” viewpoint of the crystal structure of mouse mu opioid receptor, where the side chain of the mutated positions in wsMUR are depicted as blue spheres. The
upon addition of cholesterol, which has been found to modulate the stability of several GPCRs [14,36]. The inclusion of cholesterol caused a shift of the melting point from 82.9°C to 89.3°C, suggesting that it may stabilize the helical structure of wsMUR-TM (Figure 5) [14,36].

CD and intrinsic tryptophan fluorescence were used to probe disulfide bond formation [37] in the water-soluble variant. The structure of wsMUR-TM was monitored with increasing concentrations of urea and the reducing agent 2-mercaptoethanol (2-ME). After addition of urea, the molar ellipticity at 222 nm and the intensity of the intrinsic tryptophan fluorescence of wsMUR-TM decreased. Even in 8 M urea, the protein retains some helical structure (Table 2). Upon addition of 2-ME, both the molar ellipticity and fluorescence further decreased, becoming more pronounced at the higher concentration of the reducing agent (200 mM). Thus the presence of an intramolecular disulfide bond is corroborated in the case of wsMUR-TM.

wsMUR Binding Assay

Naltrexone binding was monitored using a competitive TR-FRET (time-resolved fluorescence resonance energy transfer) based assay with fluorescently labeled wild type MUR and a naltrexone-derived antagonist. The ratio of fluorescence emission at 665 nm and 620 nm decreased in a dose-dependent manner with increasing concentrations of wsMUR-TM. The determined $K_i$ values for naltrexone were $65 \pm 1.8$ nM (wsMUR-TM) (Figure 6). As a negative control, human serum albumin (HSA, a soluble helical protein), rather than a water-soluble variant, was introduced with no significant change in the fluorescence ratio upon HSA addition.

Discussion

Computational Design of wsMUR-TM

For many membrane proteins, the local environments of residues in the interior of the protein are similar to those observed in the interiors of globular proteins [38–41]. For such proteins, the exterior lipid-contacting residues, which are predominantly hydrophobic, could in principle be redesigned so as to yield a more water-soluble variant. This requires reliable structural information to determine which residues are on the exterior of the protein in the transmembrane region. Computational methods have been used to guide such redesign. The transmembrane domains of Streptomyces lividans (KcsA) [4,42] and the z1 subunit of the nicotinic acetylcholine receptor (nAChR) from Torpedo marmorata [5] have been redesigned resulting in mutations to 30% and 18% of the respective receptors [4,5,43]. The water-soluble variants retain structural and functional features of the parent membrane proteins. In these studies, experimentally derived structural information guided the selection of exterior residues and the computational redesign at these selected sites.

Herein, the computational redesign approach was extended to design functional water-soluble variant of a human GPCR without explicit a priori experimental structural information (when the effort was initiated). The GPCR system studied here is the largest protein yet targeted for solubilization via redesign (53 out of 298 residues, approximately 18% of the protein). The human MUR was selected due to its pharmacological relevance to understanding pain management and opioid addiction. wsMUR-TM was expressed in large quantities in a heterologous bacterial system and displayed structural and functional characteristics comparable with those of the native receptor.

The computationally guided redesign requires a structural model of the protein. Two aspects of the redesign process are expected to be sensitive to the accuracy of the model structure: the identification of exterior, transmembrane positions that are targeted for redesign and the amino acid probabilities used to determine the redesigned sequence. Given the similarity of known GPCR structures and the quality of the structures that can be obtained with comparative modeling, of these two aspects we expect the amino acid probabilities to be more sensitive to the detailed structural features of a given model structure. The recent structure of the closely related murine MUR provides an opportunity to evaluate the quality of the modeled structure and the location of the mutated positions in wsMUR-TM [15]. The human and mouse receptors have 94% sequence identity. The comparative model of the human MUR and the murine crystal structure superimpose well, particularly in the transmembrane region [35]. However, five targeted positions in wsMUR-TM were not located in the exterior of the murine structure (T120E, V130K, N232D, K305G, and A306K). These five positions residues were not among the eleven that directly contact the ligand in the crystal structure; these residues compose the “binding site” and are those having an atom within 4 Å of the β-FNA ligand present in the crystal structure [15]. Thus, the binding properties of the wsMUR-TM are expected to be comparable with those of the native mu opioid receptor as demonstrated in this study. Although additional binding sites could potentially be introduced via computational redesign of the protein, we would not expect these to have affinities comparable to the wild type protein. In future work, details of the binding site of the wsMUR-TM can potentially be resolved using high-resolution structural approaches like NMR and x-ray crystallography.
GPCR Expression in E. coli and Protein Purification

The expression of several GPCRs in E. coli has been achieved [44], but obtaining functional GPCRs in large quantities has generally been challenging. While functional human MUR has previously been successfully expressed in E. coli [45], the protein appeared as part of a fusion construct and was obtained at a low yield and remained unpurified. To our knowledge, successful induction of useful amounts of native MUR without a fusion partner (or with a His-tag) in E. coli has not been reported. The apparently toxic effects of the human MUR to the cells may explain the lack of such reports. Such toxicity was also observed in this study in attempts to express the native human MUR with a His-tag. However, production of His-tagged computationally designed human MUR variant (wsMUR-TM) was achieved. Thus, the toxicity of the native receptor appears to arise from hydrophobic residues located on the exterior surface of the receptor’s transmembrane region. The ability to express and purify large amounts of functional GPCRs from E. coli should greatly accelerate studies of the structure-function relationships for such receptors.

Since an initial exposure to 0.1% SDS was required during purification, the purified wsMUR-TM in solution may still contain small amounts of SDS due to the difficulty of removing SDS from proteins. In order to avoid protein aggregation, 0.01% of SDS was utilized in the final buffer solutions for functional assays. Using binding and crystallographic studies, we have shown that such small amounts of SDS do not disrupt the tertiary structure and/or the ligand binding capabilities of some proteins [46]. Conversely, much higher concentration of SDS (0.1%) and other anionic detergents are required for the “solubilization” of the native human MUR [47].

Protein Structure Characterization and Thermostability

Consistent with the secondary structure of the native human MUR expressed in yeast [48,49], the CD spectra of the wsMUR-TM displayed a predominantly helical structure (48%) which is comparable with the native full length MUR [48]. Lower percentage of the helical content in the native full length MUR in the literature may be due to the inclusion of the N and C terminus and the higher concentration of the detergent (0.1% SDS).

Intrinsic tryptophan fluorescence was used to provide qualitative information of the conformations adopted by the water-soluble receptors; wsMUR-TM contains just six tryptophan residues (W135, W194, W228, W230, W295, and W320). Of particular interest are the tryptophan residues located in the partially buried transmembrane locations of the model structure (underlined above). The fluorescence associated with these residues is expected to be sensitive to the local hydrophobic environment and overall folding of the protein. The observed decrease in the tryptophan fluorescence and the red shift in the emission with increasing denaturant (urea) concentration

---

Table 1. Helical content comparison for the native and engineered receptors.

| 205–260 nm          | wsMUR-TM (pH 7.0 in NaHPO₄) | Native MUR (pH 7.0+0.1% SDS) |
|---------------------|-----------------------------|------------------------------|
| Helix               | 48.0%                       | 40.6%                        |
| Turn                | 14.6%                       | 18.9%                        |
| Others              | 37.4%                       | 40.5%                        |

wsMUR-TM: transmembrane-only water-soluble human mu receptor variant; MUR: human mu receptor.
doi:10.1371/journal.pone.0066009.t001

Figure 4. Mean residue ellipticity at 222 nm of wsMUR-TM in buffer solution (5 mM sodium phosphate, pH = 7.0) as a function of temperature, from 10 to 90°C. The spectrum of wsMUR-TM showed significant change near 62°C and an almost complete loss in molar ellipticity at 90°C. doi:10.1371/journal.pone.0066009.g004

Figure 5. Molar circular dichroism (CD) derived percentage of the original helical content (determined at 222 nm) of wsMUR-TM in the absence (black dots) and the presence (red dots) of cholesterol in buffer solution (5 mM sodium phosphate, 0.01% SDS, pH = 7.0) as functions of the temperature. The addition of cholesterol stabilized the wsMUR-TM as indicated by the rightward shift of the thermostability curve. doi:10.1371/journal.pone.0066009.g005
The decrease of the tryptophan fluorescence under denaturing conditions and in the presence of 2-ME is consistent with the changes in CD spectra observed under similar conditions. The requirement of the reducing agent to fully denature and unfold the protein indicates the relevance of an intramolecular disulfide bond in stabilizing the receptor structure. Although these observations suggest the presence of a disulfide bond, they do not specify which bond is formed given the existence of 11 cysteine residues in wsMUR-TM. However, the CD and ligand-binding studies are consistent with the adoption of the proper protein tertiary structure and by extension with the formation of the correct disulfide bond.

With the exception of rhodopsin, GPCRs are not generally stable and this represents one of the major obstacles for structural studies [10]. Many strategies have been employed to overcome this problem, such as the use of stabilizing ligands [50], stabilizing mutations [51], and high salt concentrations in solution [13]. In the present study, wsMUR-TM that is both soluble in aqueous media and thermally stable was successfully generated by redesigning the protein. The thermostability of wsMUR-TM improved significantly in the presence of cholesterol. These results are consistent with recent observations that the introduction of cholesterol hemisuccinate increases the thermostability of the A2A adenosine receptor in detergent micelles [14]. Studies have demonstrated that interactions between cholesterol and GPCRs can play an important role in modulating the structural stability as well as the function of the receptors [36,52]. Moreover, cholesterol is present in the recently solved crystal structure of the murine mu opioid receptor [15]. Two mechanisms have been proposed regarding cholesterol and membrane proteins: a) direct interaction between the receptor and the cholesterol molecule [36] and/or b) a modification of the membrane microenvironment of the protein by cholesterol [53]. Given that the experiments here were performed in aqueous solution, the first mechanism appears to apply to the interactions with wsMUR-TM. One of the disadvantages of designing a water-soluble variant of an integral protein is the inability to study the mechanism of the membrane microenvironment modification given the absence of a membrane. Despite this limitation, it is noteworthy that the mutations of the lipid-contacting positions do not preclude the well-known interactions that exist between the native receptor and relevant molecules such as cholesterol. The finding that the wsMUR-TM thermostability increased in the presence of cholesterol together with the previous finding that the water-soluble z1 subunit of the nicotinic acetylcholine receptor (nAChR) recovers the protein-lipid interactions of the native receptor [5,54], supports the power and flexibility of the solubilization approach in maintaining similar interactions as those seen in the native membrane-soluble protein.

### Ligand Binding Properties of the wsMUR-TM

A recently developed methodology which uses a fluorescently labeled ligand and the native MUR [55] was used to investigate the ligand-binding capabilities of the water-soluble receptors. This binding assay has been applied to study several GPCRs and particularly to MUR, where the \( K_i \) values for the morphinan opioids naloxone and naltrindole were estimated (5.1 nM and 8.1 nM for naloxone and naltrindole, respectively) and found to be in agreement with values obtained using other techniques [55]. wsMUR-TM competes with native MUR expressed in HEK293 cells for the potent opioid antagonist naltrexone. This study clearly demonstrates that the wsMUR-TM can compete with the native MUR for the fluorescent antagonist with binding affinities in nM range. The HSA (negative control) results indicate that the interaction of the water-soluble variant with naltrexone is selective and specific.

### Conclusions and Future Directions

The findings reported in this study open new tools for the characterization of GPCRs and the human MUR. The computational design approach could be applied more broadly to other receptors in the GPCR superfamily, particularly those whose structure may not be known a priori, via the use of comparative

---

**Table 2. Effects of denaturant and reducing agent on the wsMUR-TM.**

|                      | None       | Urea (8 M) | Urea (8 M) 2-ME (25 mM) | Urea (8 M) 2-ME (200 mM) |
|----------------------|------------|------------|-------------------------|--------------------------|
| Molar Ellipticity (%; 222 nm) | 100.0      | 40.0       | 25.1                    | 0.0                      |
| Fluorescence Peak Intensity (%; 300–350 nm) | 100.0      | 28.4       | 23.9                    | 4.5                      |

wsMUR-TM: transmembrane-only water-soluble human mu receptor variant; values are normalized to the condition without denaturant or reducing agent (None). 2-ME: 2-mercaptoethanol.

doi:10.1371/journal.pone.0066009.t002
(homology) modeling. The wsMUR-TM over-expressed in the E. coli system would be amenable for NMR spectroscopy and other structural studies in the presence and absence of opioid ligands. The water solubility of the receptor and its high yield in a bacterial production system offer great advantages for further pharmacological characterization as well as drug refinement and discovery.

Acknowledgments

The authors appreciate the outstanding technical support from Dr. Fang Xie, Dr. Min Li at the Department of Anesthesiology and Critical Care at the University of Pennsylvania. Dr. Renyu Liu thanks the mentorship and valuable discussions from Dr. Roderic G. Eckenfroh and the support from the Department of Anesthesiology and Critical Care at the University of Pennsylvania.

Author Contributions

Conceived and designed the experiments: JGS RL. Performed the experiments: JMP-A JX FM XC BS JGS RL. Analyzed the data: JMA-A JX FM XC BS JGS RL. Contributed reagents/materials/analysis tools: JGS RL. Wrote the paper: JMA-A JX FM XC BS JGS RL.

References

1. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogous groups, and fingerprints. Mol Pharmacol 63: 1256–1272.
2. Damil R, MacDermaid CM, Perez-Aguilar JM, Saven JG (2011) Theoretical and computational protein design. Annu Rev Phys Chem 62: 129–149.
3. Perez-Aguilar JM, Saven JG (2012) Computational design of membrane proteins. Structure 20: 5–14.
4. Slovic AM, Kono H, Lear JD, Saven JG, DeGrado WF (2004) Computational design of water-soluble genomes of the potassium channel KcsA. Proc Natl Acad Sci U S A 101: 1828–1833.
5. Cui T, Mosrey D, Bondoneno V, Tillman T, Ma D, et al. (2011) NMR structure and dynamics of a designed water-soluble transmembrane domain of nicotinic acetylcholine receptor. BiBA - Biomembranes 1118: 617–628.
6. Iurussi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18: S3–13.
7. Volkow ND, McLellan TA, Cotoo JH, Karruban M, Weiss SR (2011) Characteristics of opioid prescriptions in 2009. JAMA 305: 1299–1301.
8. Manchikanti L, Lockwood J, Agrawal A (2008) Therapeutic opioids: a new perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 11: S63–88.
9. Kuehn BM (2007) Opioid prescrption soars: increase in legitimate use as well as abuse. JAMA 297: 1236–1241.
10. Cherezov V, Abola E, Stevens RC (2010) Recent progress in the structure of the opioid receptor models. JAMA 293: 77–88.
11. Schioth HB, Fredriksson R (2005) The G-protein-coupled receptor family. Annu Rev Phys Chem 56: 27–51.
12. Cherezov V, Vebol JH, Kaufman A, MacKinnon R (2001) Chemistry of ion coordination and hydration revealed by a K+ channel-Fab complex at 2.0 A crystal structure. J Mol Biol 342: 571–583.
13. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, et al. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318: 1258–1265.
14. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, et al. (2012) Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337: 232–236.
15. Manglik A, Kruse AG, Kobaltsa TS, Thian FS, Mathiesen JM, et al. (2012) Crystal structure of the mu-opioid receptor bound to a morphinan antagonist. Nature 485: 327–332.
16. Wu H, Wacker D, Mileni M, Katrich V, Han GW, et al. (2012) Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485: 307–311.
17. Jain E, Bairoch A, Duvaud S, Phan I, Redaschi N, et al. (2009) Infrastructure for alignement search tool. J Mol Biol 215: 403–410.
18. Miyazawa A, Fujiyoshi Y, Unwin N (2003) Structure and gating mechanism of the nicotinic acetylcholine receptor. Nature 423: 949–955.
19. Zhou Y, Morais-Cabral JH, Kaufman A, MacKinnon R (2001) The structure of the delta-opioid receptor bound to naltrindole. Nature 485: 400–404.
20. Hong D, Rask-Andersen H, Schioth HB (2004) Chemistry of ion coordination and hydration revealed by a K+ channel-Fab complex at 2.0 A resolution. Nature 414: 43–48.
21. Stanasila L, Massotte D, Kieffer BL, Pattus F (1999) Expression of delta, kappa and mu opioid receptor subtypes in bacterial “fusảile ls” cytochrome revises alters ligand binding but does not prevent receptor targeting to the cell plasma membrane. Brain Res Mol Brain Res 72: 193–204.
22. Rees DC, Steenino L, Eisenberg D (1989) Hydrophobic organization of membrane-proteins. Science 245: 510–513.
23. Illegger K, Kauko A, Elsason A (2011) Why are polar residues within the membrane core evolutionary conserved? Proteins 79: 79–91.
24. Wallin E, Tsukahara T, Yoshikawa S, von Hejne G, Elsåson A (1997) Architecture of helix bundle membrane proteins: an analysis of cytochrome c oxidase from bovine mitochondria. Protein Sci 6: 808–815.
25. Begum T, Weinstein H (2004) A knowledge-based scale for the analysis and prediction of buried and exposed faces of transmembrane domain proteins. Bioinformatics 20: 1822–1835.
26. Bromin J, Lee OS, Saven JG (2006) Molecular Dynamics Simulation of WSK-3, a Computationally Designed, Water-Soluble Variant of the Integral Membrane Protein KcsA. Biophy J 90: 1156–1163.
27. Ma D, Tillman TS, Wang L, Moritsch S, Ezenkoff R, et al. (2008) NMR studies of a channel protein without membranes: structure and dynamics of water-solubilized KcsA. Proc Natl Acad Sci U S A 105: 16537–16542.
28. Kreplin D, Wong K, Gawrisch K, Yeliseyev A (2006) Bacterial expression of functional, biotinylated peripheral cannabinoid receptor CB2. Protein Expr Purif 49: 69–79.
29. Stanasila I, Massotte D, Kieffer BL, Patou F (1999) Expression of delta, kappa and mu human opioid receptors in Escherichia coli and reconstitution of the high-affinity state for agonist with heteromeric G proteins. Eur J Biochem 260: 439–448.
30. Liu R, Bu W, Xi J, Mortazavi SR, Cheung-Lau JC, et al. (2012). Beyond the deterrent effect: a binding site for sodium dodecyl sulfate (SDS) in mammalian aporefin. Acta Crystallogr D Biol Crystallogr 68: 97–104.
31. Sarramegna V, Muller I, Saven JG (1992) Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A 89: 10915–10919.
32. Sarramegna V, Muller I, Saven JG (2005) Solubilization, purification, and mass spectrometry analysis of the human mu-opioid receptor expressed in Pichia pastoris. Protein Expr Purif 43: 85–93.
33. Muller I Sarramegna V, Muller I, Alton JF (2010) The N-terminal end truncated mu-opioid receptor full expression to circular dichroism analysis. Appl Biochem Biotechnol 160: 2175–2186.
34. Muller I Sarramegna V, Renault M, Lafauquiere V, Semb S, et al. (2008) The full-length mu-opioid receptor: a conformational study by circular dichroism in
trifluoroethanol and membrane-mimetic environments. J Membr Biol 223: 49–57.

50. Rousseau B, Menard L, Haurie V, Taras D, Blanc JF, et al. (2007) Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology 46: 1100–1110.

51. Serrano-Vega MJ, Magnani F, Shibata Y, Tate CG (2008) Conformational thermostabilization of the beta1-adrenergic receptor in a detergent-resistant form. Proc Natl Acad Sci U S A 105: 877–882.

52. Oates J, Faust B, Atrill H, Harding P, Orvick M, et al. (2012) The role of cholesterol on the activity and stability of neurotensin receptor 1. Biochim Biophys Acta 1818: 2228–2233.

53. Ohvo-Rekila H, Ramstedt B, Leppimaki P, Slotte JP (2002) Cholesterol interactions with phospholipids in membranes. Prog Lipid Res 41: 66–97.

54. Nury H, Van Renterghem C, Weng Y, Tran A, Baaden M, et al. (2011) X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel. Nature 469: 420–431.

55. Zwier JM, Roux T, Cotter M, Duroux T, Douzon S, et al. (2010) A fluorescent ligand-binding alternative using Tag-lite(R) technology. J Biomol Screen 15: 1248–1259.

56. Frishman D, Argos P (1995) Knowledge-based protein secondary structure assignment. Proteins 23: 366–379.